Omeros (STU:3O8) Cyclically Adjusted PB Ratio: (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3O8 Omeros Corp STU:3O8
33 GF Score
Price €16.50
! 6 Warning Signs
View Full Analysis

What is Omeros Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Omeros  (STU:3O8) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Omeros Cyclically Adjusted PB Ratio Related Terms


Omeros Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Omeros's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omeros Cyclically Adjusted PB Ratio Chart

Omeros Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Omeros Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:3O8 vs STTK, BBOT, XOMA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Omeros's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Omeros's Cyclically Adjusted PB Ratio falls into.


STU:3O8
33GF Score
Omeros Corp STU:3O8
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omeros Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Omeros's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Omeros's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.618/333.9520*333.9520
=-0.618

Current CPI (Jun. 2026) = 333.9520.

Omeros Quarterly Data

Book Value per Share CPI Adj_Book
201609 -0.473 241.428 -0.654
201612 -0.810 241.432 -1.120
201703 -1.024 243.801 -1.403
201706 -1.098 244.955 -1.497
201709 0.161 246.819 0.218
201712 -0.049 246.524 -0.066
201803 -0.491 249.554 -0.657
201806 -0.994 251.989 -1.317
201809 -1.556 252.439 -2.058
201812 -1.796 251.233 -2.387
201903 -2.185 254.202 -2.870
201906 -2.344 256.143 -3.056
201909 -2.565 256.759 -3.336
201912 -1.810 256.974 -2.352
202003 -2.189 258.115 -2.832
202006 -2.627 257.797 -3.403
202009 -1.203 260.280 -1.544
202012 -1.609 260.474 -2.063
202103 -2.995 264.877 -3.776
202106 -3.271 271.696 -4.021
202109 -3.570 274.310 -4.346
202112 0.336 278.802 0.402
202203 -0.071 287.504 -0.082
202206 -0.493 296.311 -0.556
202209 -0.746 296.808 -0.839
202212 1.287 296.797 1.448
202303 0.817 301.836 0.904
202306 0.301 305.109 0.329
202309 -0.208 307.789 -0.226
202312 -0.375 306.746 -0.408
202403 -1.133 312.332 -1.211
202406 -1.998 314.175 -2.124
202409 -2.397 315.301 -2.539
202412 -3.004 315.605 -3.179
202503 -3.402 319.799 -3.553
202506 -3.303 322.561 -3.420
202509 -2.681 324.800 -2.757
202512 -1.445 324.054 -1.489
202603 -0.761 330.213 -0.770
202606 -0.618 333.952 -0.618

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Omeros Business Description

Other Exchanges OMER:USA0KBU:UK
Address 201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
33GF Score

Get the complete analysis for STU:3O8

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.50
Price